ATF3 and hepatocellular carcinoma: Second, patient-derived organoids and single-cell transcriptomic approaches could be employed to validate the ATF3-SLC7A7-mTORC1 axis across different HCC subtypes, facilitating the stratification of patients who might benefit from targeted therapies.